Complete the closing of the immuno-oncology collaboration with Junshi Biosciences
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 24 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Upon satisfaction of closing conditions, which is expected to occur in the first quarter 2021, Coherus and Junshi Biosciences will co-develop toripalimab”
What we found
Evidence strength A What the grades mean
The filings show the collaboration agreement was entered into on February 1, 2021, and a $145.0 million upfront payment for exclusive rights was recorded in Q1 2021, implying closing within the quarter.
-
A Coherus BioSciences, Inc. 10-Q filed 2021-05-06
“We recorded research and development expense of $145.0 million during the three months ended March 31” ✓ confirmed on the page
-
A Coherus BioSciences, Inc. 10-Q filed 2021-05-06
“On February 1, 2021, the Company entered into an Exclusive License and Commercialization Agreement (the “Collaboration Agreement”) with Junshi Biosciences” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Transaction other
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Junshi Biosciences immuno-oncology collaboration closing
- Where
- United States and Canada
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to satisfaction of closing conditions; subject to regulatory clearance to close the collaboration
- Depends on
- Regulatory, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Coherus BioSciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CHRS-024360 · Corrections policy